US HB4404 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 8-0)
Status: Introduced on September 19 2019 - 25% progression, died in committee
Action: 2019-09-20 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 19 2019 - 25% progression, died in committee
Action: 2019-09-20 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.
Title
Depression Side Effect Labeling Awareness Act of 2019
Sponsors
Rep. Bobby Rush [D-IL] | Rep. Sheila Jackson-Lee [D-TX] | Rep. Debbie Dingell [D-MI] | Rep. Andre Carson [D-IN] |
Rep. Susan Wild [D-PA] | Rep. Bennie Thompson [D-MS] | Rep. Alcee Hastings [D-FL] | Rep. Michael San Nicolas [D-GU] |
History
Date | Chamber | Action |
---|---|---|
2019-09-20 | House | Referred to the Subcommittee on Health. |
2019-09-19 | House | Referred to the House Committee on Energy and Commerce. |
2019-09-19 | House | Introduced in House |
Subjects
Administrative law and regulatory procedures
Consumer affairs
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Health
Mental health
Consumer affairs
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Health
Mental health
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/4404/all-info |
Text | https://www.congress.gov/116/bills/hr4404/BILLS-116hr4404ih.pdf |